(Alliance News) - AstraZeneca PLC on Friday said it has resumed its phase 2/3 clinical trial of Covid-19 vaccine AZD1222 in Japan after talks with the Japanese Pharmaceuticals & Medical Devices Agency.
The FTSE 100-listed pharmaceutical firm said a standard review process triggered a voluntary pause to vaccination across all global trials on September 6 so that an independent committee could review safety data.
Trials were paused in September after a UK volunteer developed an unexplained illness. Astra had already restarted its trials in the UK, as well as in Brazil, South Africa and India.
However, trials in the US have yet to resume, and Astra is still working with the US Food & Drug Administration "to facilitate review of the information needed to make a decision regarding resumption of the US trial", it said Friday.
Shares in Astra were down 0.2% at 8,466.00 pence in London in morning trading.
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)